MV-4-11; Myelomonocytic Leukemia; Human (Homo sapiens) Item ID: ATCCRL9591
| Permits and Restrictions |
View Permits |
|---|---|
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Cell Type | macrophage |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | biphenotypic B myelomonocytic leukemia |
| Age | 10 years |
| Gender | male |
| Applications | This cell line is a suitable transfection host. |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype | 48, XY, t(4;11)(q21;q23), +8, +19 |
|---|---|
| Derivation | The MV4-11 cell line was established by Rovera and associates from the blast cells of a 10-year-old male with biphenotypic B-myelomonocytic leukemia. The growth factor, granulocyte/macrophage colony-stimulating factor (GM-CSF), was required to establish this cell line and growth factors are necessary for its continuous proliferation in chemically defined medium [PubMed: 3496132]. |
| Clinical Data | male The MV4-11 cell line was established by Rovera and associates from the blast cells of a 10-year-old male with biphenotypic B-myelomonocytic leukemia. |
| Antigen Expression | CD4; Homo sapiens CD10; Homo sapiens CD15, human; Homo sapiens CD4 (40-96%); CD10 (4-11%); CD15 (96-99%) |
| Genes Expressed | CD4; Homo sapiens, CD10; Homo sapiens, CD15, human; Homo sapiens, CD4 (40-96%); CD10 (4-11%); CD15 (96-99%) |
| Comments | This line can be propagated in medium supplemented with 10% FBS without the addition of growth factors. IL-3 can independently support the long-term growth of this cell line, but IL-3 antagonized the proliferation of MV4-11 cells in the presence of GM-CSF when both factors were used at very low concentrations. Granulocyte colony stimulating factor (G-CSF) synergized with GM-CSF in inducing proliferation of MV4-11 cells; G-CSF alone causes a transient stimulation of the cell line. This line was formerly designated ATCC HTB-189. Over 96% of these cells are positive by indirect immunofluorescence for the myelomonocytic antigen CD15, 40-96% are positive for the monocytic antigen CD4, and 4-11% are positive for CD10 [PubMed: 3500218]. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. |
|---|---|
| Subculturing | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 105 cells/mL and maintain between 1 X 105 and 1 X 106 cells/mL. Corning® T-75 flasks (catalog #431464) are recommended for subculturing this product. Medium Renewal: Every 2 to 3 days |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C Growth Conditions: If the cells are maintained in a serum-free medium, it is necessary to add the following: 0.005 mg/mL transferrin, 0.005 mg/mL insulin, and 5 ng/mL GM-CSF. |
| STR Profile | Amelogenin: X,Y CSF1PO: 10,12 D13S317: 13 D16S539: 11,12 D5S818: 11,12 D7S820: 8,9 THO1: 8,9.3 TPOX: 8,11 vWA: 14,15 |
|---|
| Name of Depositor | Wistar Institute |
|---|---|
| U.S. Patent Number | 5,516,512 |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| References |
Lange B, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 1987. PubMed: 3496132 Santoli D, et al. Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139: 3348-3354, 1987. PubMed: 3500218 If the cells are maintained in a serum-free medium, it is necessary to add the following: 0.005 mg/ml transferrin, 0.005 mg/ml insulin, and 5 ng/ml GM-CSF. |
| Permits |
These permits may be required for shipping this product to Australia:
|
|---|---|
| Basic Documentation | Product Sheet Certificate of Analysis SDS |
| References |
Lange B, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 1987. PubMed: 3496132 Santoli D, et al. Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139: 3348-3354, 1987. PubMed: 3500218 If the cells are maintained in a serum-free medium, it is necessary to add the following: 0.005 mg/ml transferrin, 0.005 mg/ml insulin, and 5 ng/ml GM-CSF. |